We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Novel Method Reclaims Resolution of Single-Cell RNA-Seq

By LabMedica International staff writers
Posted on 28 Oct 2020
Single-cell RNA sequencing (scRNA-seq) is a powerful tool to characterize cells. More...
Current scRNA-seq platforms, despite offering high throughput, are inefficient and provide low resolution among distinct cell states and molecular features.

Most high-throughput scRNA-seq methods rely on barcoding of cellular components to recover single-cell transcriptomes for thousands of cells at once. This is achieved by isolating uniquely barcoded poly-dT oligonucleotides that can capture and tag cellular messenger RNA (mRNA) during reverse transcription. In a second step, an additional oligonucleotide priming site is added to newly synthesized complementary DNA (cDNA) to enable polymerase chain reaction (PCR)-based amplification.

Medical Biochemists at the Massachusetts Institute of Technology (Cambridge, MA, USA) and their associates developed Seq-Well S3 ("Second-Strand Synthesis") as a massively parallel scRNA-seq protocol that uses a randomly primed second-strand synthesis to recover cDNA molecules to facilitate template-switching. This generates double-stranded cDNA that is labeled on one end with the SMART sequence and its reverse complement on the other, making it more accessible for PCR enzymes to amplify the molecules.

To perform the study skin biopsies were obtained from a total of 16 patients at the University of California, Los Angeles and University of Southern California Hansen’s Clinic, while an additional three samples were obtained from the University of Michigan. The team utilized Seq-Well, a massively parallel, low-input scRNA-seq platform for clinical samples, to capture the transcriptome of single cells. The team performed Templated Second-Strand Synthesis, PCR Amplification, Optimization of Second-Strand Synthesis, CD4+ T Cell comparisons of 10x Genomics, Pleasanton, CA, USA), Seq-Well S3, and Smart-Seq2, DNA Sequencing and Alignment of peripheral blood mononuclear cells (PBMC) optimization samples, and tissue immunofluorescence staining.

In total, the scientists processed 19 skin biopsies and retained over 38,000 high-quality single-cell transcriptomes using Seq-Well S3. They were able to recover 15 primary cell types. To further define biological features, the team used the method to examine subpopulations of T cells, myeloid cells, endothelial cells, dermal fibroblasts, and keratinocytes in each inflammatory condition. The team found, for example, regulatory T cells, dysfunctional NR4A1-expressing T cells, and senescent SESN3+ T cells were over-represented, potentially reflecting T-cell dysfunction in psoriasis pathology.

The team also distinguished patterns associated with multiple diseases by looking across different inflammatory skin conditions, revealing common and unique features. For instance, they found that a group of natural killer cells, γΔ T cells, and a sub-cluster of immature cytotoxic T cells are derived from leprosy and granuloma annulare, indicating common T-cell programming in both forms of inflammation.

Alex Shalek, PhD, associate professor of chemistry at MIT and a senior author of the study, said, “"It's become clear that these technologies have transformative potential for understanding complex biological systems. If we look across a range of different datasets, we can really understand the landscape of health and disease, and that can give us information as to what therapeutic strategies we might employ.” The study was published on October 13, 2020 in the journal Immunity.

Related Links:
Massachusetts Institute of Technology
10x Genomics



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Portable POCT Blood Gas Analyzer
BD100
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.